Review on Extraskeletal myxoid chondrosarcoma, with data on clinics, and the genes involved.
Classification
Extraskeletal myxoid chondrosarcoma is characterized by a lobulated architecture (A), with a reticular growth pattern of interconnecting uniform tumor cells having ovoid-to-spindled nuclei and eosinophilic cytoplasm (B).
Clinics and pathology

Disease
Malignant mesenchymal neoplasm of uncertain differentiation.
Epidemiology
Extraskeletal myxoid chondrosarcoma is a rare tumor, encompassing 2.3% of soft tissue sarcomas in a Japanese series. Mean ages reported in various series range from 46 to 57 years. Males are affected about twice as often as females.
Clinics
Location: deep soft tissues of the lower extremities in about 75% of the cases, especially the thigh, the popliteal fossa, and the buttock, and can also occur in the trunk, abdomen, and head and neck.
Pathology
Macroscopic findings: the tumor presents as lobulated or multinodular mass, generally well circumscribed with pseudocapsule. The size of the tumor at the time of diagnosis may vary from 1 to about 20 cm (median size 7 cm). Histology: Lobulated architecture with uniform round to spindled cells forming interconnecting cords, clusters, or trabeculae in a background of myxoid matrix. The tumor cells have variably eosinophilic or vacuolated cytoplasm that extends to form the reticular growth pattern. A subset of tumors shows hypercellularity, higher grade cytomorphology, and epithelioid or rhabdoid features. A subset of tumors is positive for S100, CD117, synaptophysin, and neuron-specific enolase. INI1 loss is observed in a subset, often with rhabdoid features. Ultrastructurally, at least one third of the tumors demonstrate microtubular aggregates within dilated rough endoplasmic reticulum.
Treatment
Treatment: surgical excision, with possible adjuvant chemotherapy.
Prognosis
Prognosis: high rates of local and distant recurrence, including pulmonary metastasis, but with associated prolonged survival.
Cytogenetics
NR4A3 Gene Fusions in Extraskeletal Myxoid
Chondrosarcoma t(9;22)(q22;q12) EWSR1/NR4A3 t(3;9)(q12;q22) TFG/NR4A3 t(9;11)(q22;q24) HSPA8/NR4A3 t(9;15)(q22;q21) TCF12/NR4A3 t(9;16)(q22;p11) FUS/NR4A3 t(9;17)(q22;q11) TAF15/NR4A3 Left: Karyotype of extraskeletal myxoid chondrosarcoma with t(9;22)(q22;q12). Right: Fluorescence in situ hybridization demonstrating rearrangement of NR4A3 by break apart probe.
Cytogenetics Morphological
 Recurrent gene fusions involving NR4A3 on chromosome 9 are observed in the majority of extraskeletal myxoid chondrosarcomas. The most common fusion partner is EWSR1, resulting in t(9;22)(q22;q12) with fusion of the 5' aspect of EWSR1 with NR4A3.  Uncommon gene fusion events involving NR4A3 with TAF15, TCF12, TFG, FUS, or HSPA8 have also been reported. These events result in t(9;17)(q22;q11), t(9;15)(q22;q21), t(3;9)(q12;q22), t(9;16)(q22;p11), or t(9;11)(q22;q24), respectively.  The breakpoint involving NR4A3 frequently occurs in the 5' untranslated region, with the resultant fusion including the entire NR4A3 protein. 
Genes involved and proteins
TFG (TRK-fused gene)
Protein
Core component of BAF complex.
